36552180|t|Neuropsychiatric Symptoms after Liver Transplantation in a 65-Year-Old Male Patient.
36552180|a|The development of immunosuppressants has been key for the advancement of solid organ transplant surgery. Specifically, cyclosporine, tacrolimus, or everolimus have significantly increased the survival rate of patients by reducing the risk of a rejection of the transplanted organ and limiting graft-versus-host disease. We report the case of a 65-year-old man who, after undergoing a liver transplantation and receiving an immunosuppressive treatment with cyclosporine and everolimus, presented severe obsessive, psychotic, and behavioral symptoms over the past three years, and describe the pharmacological and non-pharmacological interventions implemented against these symptoms. In this case, the immunosuppressants used have been cyclosporine and, preferably, everolimus. On the other hand, potential adverse reactions to the treatment have been observed, including neuropsychiatric symptoms such as tremor, anxiety, dysthymia, psychosis, and behavioral disorders, which make it necessary to use corrective psychoactive drugs such as benzodiazepines, antidepressants, and antipsychotics, combined with non-pharmacological interventions. A transversal approach, from the medical and psychosocial disciplines, facilitates success in managing neuropsychiatric symptoms after soft organ transplants.
36552180	0	25	Neuropsychiatric Symptoms	Disease	MESH:D001523
36552180	76	83	Patient	Species	9606
36552180	205	217	cyclosporine	Chemical	MESH:D016572
36552180	219	229	tacrolimus	Chemical	MESH:D016559
36552180	234	244	everolimus	Chemical	MESH:D000068338
36552180	295	303	patients	Species	9606
36552180	379	404	graft-versus-host disease	Disease	MESH:D006086
36552180	442	445	man	Species	
36552180	542	554	cyclosporine	Chemical	MESH:D016572
36552180	559	569	everolimus	Chemical	MESH:D000068338
36552180	588	633	obsessive, psychotic, and behavioral symptoms	Disease	MESH:D009771
36552180	820	832	cyclosporine	Chemical	MESH:D016572
36552180	850	860	everolimus	Chemical	MESH:D000068338
36552180	956	981	neuropsychiatric symptoms	Disease	MESH:D001523
36552180	990	996	tremor	Disease	MESH:D014202
36552180	998	1005	anxiety	Disease	MESH:D001007
36552180	1007	1016	dysthymia	Disease	MESH:D019263
36552180	1018	1027	psychosis	Disease	MESH:D011618
36552180	1033	1053	behavioral disorders	Disease	MESH:D001523
36552180	1124	1139	benzodiazepines	Chemical	MESH:D001569
36552180	1330	1355	neuropsychiatric symptoms	Disease	MESH:D001523
36552180	Positive_Correlation	MESH:D000068338	MESH:D011618
36552180	Positive_Correlation	MESH:D016572	MESH:D014202
36552180	Negative_Correlation	MESH:D001569	MESH:D014202
36552180	Negative_Correlation	MESH:D001569	MESH:D011618
36552180	Positive_Correlation	MESH:D000068338	MESH:D009771
36552180	Negative_Correlation	MESH:D016559	MESH:D006086
36552180	Negative_Correlation	MESH:D016572	MESH:D006086
36552180	Negative_Correlation	MESH:D000068338	MESH:D006086
36552180	Negative_Correlation	MESH:D001569	MESH:D001523
36552180	Positive_Correlation	MESH:D016572	MESH:D019263
36552180	Positive_Correlation	MESH:D016572	MESH:D001523
36552180	Comparison	MESH:D000068338	MESH:D016572
36552180	Positive_Correlation	MESH:D000068338	MESH:D001007
36552180	Positive_Correlation	MESH:D000068338	MESH:D019263
36552180	Negative_Correlation	MESH:D001569	MESH:D019263
36552180	Negative_Correlation	MESH:D001569	MESH:D001007
36552180	Positive_Correlation	MESH:D016572	MESH:D001007
36552180	Positive_Correlation	MESH:D016572	MESH:D011618
36552180	Positive_Correlation	MESH:D000068338	MESH:D001523
36552180	Positive_Correlation	MESH:D000068338	MESH:D014202
36552180	Positive_Correlation	MESH:D016572	MESH:D009771

